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ABSTRACT
Background: Stereotactic radiosurgery (SRS) has emerged as an important modality for 
the treatment of intracranial metastases. There are currently few established guidelines 
delineating indications for SRS use and fewer still regarding plan evaluation in the treat-
ment of multiple brain metastases.
Methods: An 18 question electronic survey was distributed to radiation oncologists 
at National Cancer Institute (NCI) designated cancer centers in the US (60). Centers 
without radiation oncologists were excluded. Physicians who indicated that they do 
not prescribe SRS were excluded from the remaining survey questions. Sign test and 
Chi-square test were used to determine if responses differed significantly from random 
distribution.
Results: 116 of the 697 radiation oncologists surveyed completed the questionnaire, 
representing 51 institutions. 62% reported treating patients with brain metastases using 
SRS. Radiation oncologists prescribing SRS most commonly treat CNS (66.2%) and lung 
(49.3%) malignancies. SRS was used more frequently for <10 brain metastases (73.7%; 
p<.0001) and whole brain radiation therapy (WBRT) for >10 brain metastases (82.5%; 
p<.0001). The maximum number of lesions physicians were willing to treat with SRS 
without WBRT was 1-4 (40.4%) and 5-10 (42.4%) (p<.0001 compared to 11-15, 16-20 
and no limit). The most important criteria for choosing SRS or WBRT were number of 
lesions (p<.0001) and performance status (p=.016). The most common margin for SRS 
was 0 mm (49.1%; p=.0021). The most common dose constraints other than critical 
structure was conformity index (84.2%) and brain V12 (61.4%). The LINAC was the most 
common treatment modality (54.4%) and mono-isocenter technique for multiple brain 
metastases was commonly used (43.9%; p=.23). Most departments do not have a policy 
for brain metastases treatment (64.9%; p=.024). 
Conclusions: This is one of the first national surveys assessing the use of SRS for brain 
metastases in clinical practice. These data highlight some clinical considerations for 
physicians treating brain metastases with SRS.
Summary: This is among the first national surveys to assess the use of SRS for brain 
metastases in clinical practice. Specifically, radiation oncologist reported increasingly 
using SRS instead of WBRT for treating 
<10 metastases, with the LINAC being 
the most common modality. Further, 
treatment parameters considered the 
most important included 0 mm margins, 
conformity index, brain V12, and mono-
isocenter technique for multiple brain 
metastases. These results may provide 
context regarding the use of SRS for brain 
metastases in clinical practice.
INTRODUCTION
Brain metastases are a significant cause 
of morbidity and mortality among 
oncologic patients, affecting 20-40% 
of this population.1 Several therapeutic 
strategies for intracranial metastases 
exist, including stereotactic radiosurgery 
(SRS), whole brain radiotherapy (WBRT), 
surgical resection and supportive care 
with steroids, though systemic therapy 
remains an option for patients with 
selected cancers.2 WBRT was historically 
the treatment modality of choice for 
brain metastases with or without surgical 
resection.3,4 Technological improvements 
in Gamma Knife and LINAC-based SRS 
coupled with data indicating decreased 
cognitive toxicity with SRS5, have led to 
increased utilization of SRS6. Although 
evidence-based clinical practice guide-
lines exist for the use of SRS for brain 
metastases,7-12 there are comparatively 
fewer reports that study specific aspects 
of SRS plan evaluation or if current 
use reflects the recommendations of 
professional societies. In that context, 
the current study represents one of the 
few national surveys which specifically 
investigates these issues to clarify the 




An 18 question, non-incentivized elec-
tronic survey was distributed to radiation 
oncologists at National Cancer Institute 
Stereotactic Radiosurgery Practice Patterns 
for Brain Metastases in the United States: 
A National Survey
Erik Scott Blomain, BA1; Hyun Kim, MD1; Shivank Garg, MD1; Deepak 
Bhamidipati, BS1; Jenny Guo, BS1; Ingrid Kalchman, BS1; John McAna, PhD2 
and Wenyin Shi, MD, PhD1
1 Department of Radiation Oncology, Thomas Jefferson University, Sidney Kimmel Cancer 
Center at Jefferson, Philadelphia, PA 
2 Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA
1
Blomain et al.: Stereotactic Radiosurgery Practice Patterns for Brain Metastases in the US
Published by Jefferson Digital Commons, 2018
37JHN JOURNAL 
Stereotactic Radiosurgery Survey 
five years. While the survey did not eval-
uate the role insurers play in physicians’ 
decision making, private insurance typi-
cally recognizes the role of SRS in treating 
multiple brain metastases with no clear 
maximum identified.18 Additionally, citing 
a growing body of literature regarding 
safety and efficacy, current National 
Comprehensive Cancer Network (NCCN) 
recommendations for SRS alone do not 
specify a maximum number of lesions.19 
Knisely et al first examined the use of 
SRS in clinical practice several years ago; 
physicians at two conferences hosted by 
national stereotactic radiosurgery soci-
eties were asked to fill a questionnaire, 
with a majority of respondents consid-
ering it “reasonable” to treat greater 
than 5 metastases with SRS alone.20 
More recently, Sandler et al evalu-
ated practicing physicians’ “cutoff” for 
treating brain metastases with SRS alone 
versus WBRT, among other scenarios.21 
Importantly, they found CNS-specialists 
to be comfortable treating a mean of 
8.1 lesions compared to 5.6 and 5.1 
lesions for low-volume CNS specialists 
and non-CNS specialists respectively.21 
While our survey did not stratify SRS use 
according to specialization, our results 
reflect a similar trend among physicians 
at a national level for treating greater than 
five lesions with SRS alone. 
Notably, recent American Society for 
Therapeutic Radiology and Oncology 
(ASTRO) Choosing Wisely guidelines 
recommend against using adjuvant 
WBRT with SRS, and instead recom-
mend SRS monotherapy for brain 
metastases.12,22 However, no guidance is 
provided regarding the SRS plan evalua-
tion. The present study identifies several 
parameters in current SRS use for brain 
metastasis in practice, including the use 
of 0 mm margins, conformity index, brain 
V12, and the mono-isocenter technique 
for multiple brain metastases. While our 
survey did not specifically assess the 
values used for each parameter, retro-
spective data indicate that V12 greater 
than 10.9 cm3 is associated with a 51% 
1 year risk of radionecrosis.23 Likewise, 
other treatment parameters appear to 
play an important role in the development 
of a safe and effective treatment plan.
The overall response rate was low for 
this study, introducing the potential for 
number of lesions (p<.0001), histology 
(p=.0014), performance status (p=.016) 
and location (p<.0001) as determined by 
sign-test. Leptomeningeal disease was 
statistically significant versus all other 
choices as the predominant contraindi-
cation to prescribing SRS without WBRT 
(93%; CI [83-98%]). 
Treatment Modality and Planning 
LINAC (54.4%) was more commonly 
used than the CyberKnife (14.0%) or 
Gamma Knife (31.6%) for SRS treat-
ment (p=.0009). The mono-isocenter 
technique for multiple brain metastases 
was commonly used (43.9%; p=.23). The 
most common margin for SRS was 0 mm 
(49.1%; p=.0021), with 38.6% and 12.3% 
prescribing a 1 mm and 2 mm margin, 
respectively. The most common dose 
constraints other than critical structure 
were conformity index (84.2%) and V12 
(61.4%). Diameter, volume and histology 
of lesion were all ranked as significant 
in determining the SRS prescription 
dose (sign-test, p<.0001, p=.001 and 
p<.0001, respectively). Notably, most 
departments do not have a policy in 
place for treating brain metastases with 
SRS (64.9%; p=.024). 
DISCUSSION
Despite increasing use of SRS to treat 
brain metastases, little exists in terms 
of guidance for physicians using this 
modality. Moreover, our data indicate that 
most departments do not have policies 
governing SRS use. Importantly, no clear 
guidelines exist regarding the maximum 
number of metastases for which SRS is 
recommended, despite a historically-
used cutoff of 4 in clinical trials.5,13,14 In 
this study, 42.4% of respondents reported 
using SRS for patients with 5-10 metas-
tases and 17.5% of respondents offering 
it for more than 10 lesions without WBRT. 
Thus, a significant number of respondents 
are using SRS for more than the standard 
4 lesions. In total, 73.7% of respondents 
reported using SRS more often for <10 
metastasis, and 82.5% used WBRT more 
often for >10 lesions. These physicians 
may be influenced by a shifting paradigm 
towards SRS alone for a greater than 5 
or greater than 10 lesions.15-17 Indeed, 
the majority of respondents reported 
increasing their use of SRS over the last 
designated cancer centers in the United 
States (60). Centers without radiation 
oncologists were excluded. The total 
number of physicians contacted was 697. 
Physicians who reported not prescribing 
SRS were not invited to complete 
remaining survey questions. Per institu-
tional policy, this study was IRB-exempt.
Statistical Analysis 
Depending on type of question, 95% 
confidence interval (estimate of propor-
tion), sign test (difference from expected 
mean) or Chi-square test (difference 
from expected distribution) were used 
to determine if responses differed 
significantly from random distribution. 
All data analyses were completed using 
Stata software and a P value < 0.05 was 
considered to be statistically significant.
RESULTS
Response and Demographic Data 
All survey results are reproduced in 
Table 1. Of 697 physicians surveyed, 118 
(16.9%) responded, with 28.7% reporting 
that they do not treat brain metastases 
with SRS. Respondents represented 51 
different institutions across 28 states 
with varying years of practice experience. 
Indications and Use in Practice 
Respondents primarily treated CNS (66.2%, 
95% CI [54-77%]); lung was numerically 
the second most commonly treated 
disease site (49.3%). SRS (73.7%) was 
used more frequently than WBRT (10.5%) 
for <10 brain metastases (p<.0001) while 
WBRT (82.5%) was used more frequently 
than SRS (5.3%) for >=10 brain metas-
tases (p<.0001). The maximum number 
of lesions physicians were willing to treat 
with SRS without WBRT in the treatment 
session was 1-4 (40.4%) and 5-10 (42.4%) 
(p<.0001; compared to 11-15, 16-20 and 
no limit). Most physicians reported they 
would not treat more than 10 lesions 
over multiple sessions with SRS (43.9%; 
p=.0003) but 19.3% reported there was 
no limit to the number they would treat. 
Physicians indicated that their practice 
had changed in the past 5 years by more 
frequently using SRS without WBRT 
(84.2%) and SRS without other treatments 
(i.e. surgery or WBRT; 82.5%). Criteria used 
to determine SRS versus WBRT use were 
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response bias. Despite this potential 
limitation, emerging research suggests 
that low response rates are not inher-
ently associated with inaccurate results 
or nonresponder bias.24,25 Moreover, the 
wide geographic spread and distribution 
of practice experience among respon-
dents suggests that the current sample 
was representative of the academic field 
at large. As this survey was distributed to 
physicians practicing at NCI-designated 
cancer centers however, the responses 
may not be reflective of the patterns 
of SRS use in private practice. Another 
potential limitation of the survey was 
that it did not account for patient volume 
per institution, which may be a surrogate 
for expertise in SRS and could influence 
aggressiveness in treating multiple brain 
metastases. Furthermore, individual 
practitioners were not asked about their 
patient volumes, which may be a surro-
gate for clinical versus research time in an 
academic setting and therefore influence 
management preferences. Future studies 
will be needed to continue to address 
these issues and refine clinical practice. 
CONCLUSIONS
To our knowledge, this is among the first 
national assessments of the use of SRS 
for brain metastases in clinical practice 
in the U.S. The data indicate that radia-
tion oncologists are increasingly using 
SRS for the treatment of intracranial 
lesions, even in situations which were 
historically treated with WBRT. Treatment 
parameters considered most by respon-
dents include 0 mm margins, conformity 
index, brain V12, and a mono-isocenter 
technique for multiple brain metastases. 
These data may reveal areas that require 
guidance and instruction from coopera-
tive group committees.
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